10th International Workshop on Clinical Pharmacology of HIV Therapy

Conference Reports for NATAP


10th International Workshop on Clinical Pharmacology of HIV Therapy April 15-17, 2009 Amsterdam

	10th International Workshop on Clinical Pharmacology of HIV Therapy - Written by Courtney V. Fletcher, Pharm.D. (05/18/09) First-Dose and Steady-State Pharmacokinetics of Raltegravir in the Genital Tract of HIV Negative Women - (04/30/09) Raltegravir Levels in Cervicovaginal Fluid May Prompt PEP and PrEP Studies - written by Mark Mascolini - (04/20/09) Merck Offers Unique Perspective on Second-Generation Integrase Inhibitor - written by Mark Mascolini - (04/20/09) Differing Darunavir Troughs With Once- and Twice-Daily Dosing in Practice - written by Mark Mascolini - (04/20/09) Unboosted Atazanavir Plus Raltegravir Analyzed as Two-Drug Replacement Regimen - written by Mark Mascolini - (04/20/09) Etravirine Levels Higher When Added After Darunavir vs With Darunavir - written by Mark Mascolini - (04/20/09) Enfuvirtide-to-Raltegravir Switch Lowers Levels of Darunavir and Tipranavir - written by Mark Mascolini - (04/20/09) Efavirenz Lowers Levels of Darunavir Given as 900/100 mg Once Daily With Ritonavir - written by Mark Mascolini - (04/16/09) Early Look at Once-Daily Darunavir/Ritonavir for Treatment-Experienced Patients - written by Mark Mascolini - (04/16/09) How Much (or How Little) Ritonavir Do You Need to Boost Another PI? - written by Mark Mascolini - (04/16/09) Lopinavir/Ritonavir Monotherapy as an Antiretroviral Stopping Strategy - written by Mark Mascolini - (04/16/09) Genetic Markers Tied to Early Discontinuation of Three Antiretrovirals - written by Mark Mascolini - (04/16/09)